Five things for pharma marketers to know: Monday, February 27, 2017

Share this content:


1. Pfizer said it received a subpoena from the U.S. Attorney's Office For the District of Massachusetts over its support for patient assistance programs targeting Medicare patients. The regulatory filing disclosed that Pfizer received subpoenas in 2015 and 2016 related to groups that help cover patients' co-pays. (Reuters)

2. Drugmakers appear to be responding to criticism over how they price their medicines. In January, drugmakers raised prices for fewer drugs and there were also fewer price increases of 10% or more compared to the same month last year.  (WSJ)

3. Republican congressional leaders reportedly plan to repeal and replace the Affordable Care Act in three steps. The first step would implement certain elements of their proposed new healthcare bill, such as expanding health savings accounts, and would also likely include a transition period so people don't suddenly lose their health coverage. (WSJ)

4. As Lilly's Cialis and Pfizer's Viagra approach their patent expirations, are we near the end of DTC ads for erectile dysfunction medicines? (Forbes)

5. ICYMI: Merck disclosed it would write down most of what it doled out for an experimental hepatitis C drug in 2014, saying that the market is now overcrowded. The drug, uprifosbuvir, was acquired in Merck's $3.9 billion deal to buy Idenix Pharmaceuticals. Merck said the drug's value is now $240 million. (Bloomberg)

Share this content:
Scroll down to see the next article